0K6R.LNeurocrine Biosciences, Inc.

Acerca de

Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for a range of neurological, endocrine, and psychiatric conditions. Its established portfolio offers solutions for conditions such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids. Foremost among its commercialized offerings is INGREZZA, a VMAT2 inhibitor specifically indicated for treating tardive dyskinesia. Other key commercialized therapies include ONGENTYS, a catechol-O-methyltransferase inhibitor functioning as an adjunctive treatment alongside levodopa/DOPA decarboxylase inhibitors for individuals with Parkinson's disease. Additionally, ORILISSA is available for women experiencing moderate to severe endometriosis pain, and ORIAHNN provides an oral, non-surgical option for pre-menopausal women managing heavy menstrual bleeding linked to uterine fibroids. Beyond its marketed drugs, Neurocrine Biosciences maintains a robust pipeline of investigational compounds. This includes NBI-921352, which is being developed to address both pediatric patients and adults with focal epilepsy, and NBI-827104, aimed at rare pediatric epilepsy and essential tremor. Further additions to the clinical development portfolio encompass NBI-1065845 for major depressive disorder (MDD), NBI-1065846 specifically targeting anhedonia within MDD, and NBI-118568, an agent under investigation for schizophrenia. To further its research and development efforts, the company has established strategic alliances and licensing agreements with a notable roster of partners, including Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL – Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Established in 1992, Neurocrine Biosciences, Inc. maintains its headquarters in San Diego, California.

www.neurocrine.com

Estadísticas clave

Cap. de mercado

16.79B

BPA

4.81

Rend. dividendo

0.00%

Beta

0.40

P/VC

4.34

ROE

14.7%

Sector

Healthcare

Industria

Biotechnology

CEO

Kyle W. Gano

Empleados

1800

Fecha IPO

2018-01-29

País

US